A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development

被引:5
|
作者
Sternebring, Ola [1 ]
Alifrangis, Lene [1 ]
Christensen, Toke Folke [2 ]
Ji, Hong [3 ]
Hegelund, Anne Charlotte [4 ]
Hogerkorp, Carl-Magnus [3 ]
机构
[1] Novo Nordisk AS, Dept Dev DMPK, DK-2760 Malov, Denmark
[2] Novo Nordisk AS, Dept Quantitat Clin Pharmacol, DK-2860 Soborg, Denmark
[3] Novo Nordisk AS, Dept Pharmacodynam, Novo Nordisk Pk, DK-2760 Malov, Denmark
[4] Novo Nordisk AS, Dept Dev Bioanal, DK-2760 Malov, Denmark
关键词
receptor occupancy; pharmacodynamics; flow cytometry; biomarker; clinical trial; drug development; RESEARCH-AND-DEVELOPMENT; MONOCLONAL-ANTIBODY; PHASE-I; RHEUMATOID-ARTHRITIS; CLINICAL ACTIVITY; HEALTHY-SUBJECTS; DOUBLE-BLIND; SAFETY; PHARMACOKINETICS; TRIAL;
D O I
10.1002/cyto.b.21277
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BackgroundFlow cytometry-based receptor occupancy (RO) assessments for pharmacodynamic (PD) response measurements along with drug pharmacokinetic (PK) measurements represent a cornerstone in mechanism based PK/PD modeling of drugs against cell surface targets. This report describes the utility of using a Free and a Bound assay in combination to derive RO estimations through a weighted calculation method. MethodsData from a RO assay validation study in human samples was used to explore the performance of various RO data calculation methods. The calculation methods were subsequently applied to investigate the best method to generate RO data in a first in human phase 1 clinical trial. Finally, the outcome of the analysis was used for PK/PD modeling of a prospective phase 2a trial. ResultsThe validation data assessment demonstrated that a weighted RO calculation method had a better performance in terms of precision, accuracy and dynamic range. In the phase 1 clinical trial data analysis the weighted method again demonstrated a better performance resulting in a more robust RO estimation, and subsequently also generating a more reliable PK/PD simulation for the phase 2a trial. ConclusionsThis report demonstrated the utility of using a combined Free and Bound RO assessment together with a weighted calculation method to better support mechanism-based PK/PD modeling activities. (c) 2015 International Clinical Cytometry Society
引用
收藏
页码:220 / 229
页数:10
相关论文
共 50 条
  • [41] PARAMETER ESTIMATION BY WEIGHTED MOMENTS METHOD
    ANDERSSEN, AS
    WHITE, ET
    [J]. CHEMICAL ENGINEERING SCIENCE, 1971, 26 (08) : 1203 - +
  • [42] Weighted median method for centerline estimation
    Rahn, RD
    [J]. ASQ'S 56TH ANNUAL QUALITY CONGRESS PROCEEDINGS, 2002, : 569 - 580
  • [43] Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
    Wei, Xiaohui
    Gibiansky, Leonid
    Wang, Yehong
    Fuh, Franklin
    Erickson, Rich
    O'Byrne, Sharon
    Tang, Meina T.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (03): : 386 - 398
  • [44] Drug development with pet - Is occupancy a valuable outcome measure?
    Wong, D. F.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S27 - S27
  • [45] ANTIPSYCHOTIC DRUG-THERAPY IN SCHIZOPHRENICS - STUDIES OF RECEPTOR OCCUPANCY
    HIRSCHOWITZ, J
    VALLABHAJOSULA, S
    INTRATOR, J
    HITZEMANN, R
    DACOSTA, M
    MACHAC, J
    [J]. BIOLOGICAL PSYCHIATRY, 1994, 35 (09) : 691 - 691
  • [46] Role of the pharmacokinetic-pharmacodynamic relationship in drug development
    Bellissant, E
    Courcier-Duplantier, S
    Blin, O
    [J]. THERAPIE, 2002, 57 (04): : 347 - 357
  • [47] The scopolamine model as a pharmacodynamic marker in early drug development
    Robert A. Lenz
    Jeffrey D. Baker
    Charles Locke
    Lynne E. Rueter
    Eric G. Mohler
    Keith Wesnes
    Walid Abi-Saab
    Mario D. Saltarelli
    [J]. Psychopharmacology, 2012, 220 : 97 - 107
  • [48] Pharmacodynamic aspects of drug administration.: Tolerance development
    Paalzow, LK
    Själander-Brynne, L
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1998, 33 (03) : 235 - 240
  • [49] Applications of pharmacokinetic/pharmacodynamic research in rational drug development
    Danhof, M
    [J]. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1996, 18 : 53 - 54
  • [50] The scopolamine model as a pharmacodynamic marker in early drug development
    Lenz, Robert A.
    Baker, Jeffrey D.
    Locke, Charles
    Rueter, Lynne E.
    Mohler, Eric G.
    Wesnes, Keith
    Abi-Saab, Walid
    Saltarelli, Mario D.
    [J]. PSYCHOPHARMACOLOGY, 2012, 220 (01) : 97 - 107